Women’s Health Video Recap—November 26, 2025

This biweekly women’s health video covers major regulatory shifts, coverage decisions, clinical trial outcomes, early-detection initiatives, strategic partnerships, imaging advances, and surgical innovation—plus more.

Watch Our Video Summary Capturing Top Women’s Health News from the Last Two Weeks

Dive deeper

📚 View the full Women’s health archive on our research hub page.

Transcript

Welcome to the latest edition of Women’s Health Updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.

First, new unified guidance for inflammatory bowel disease in pregnancy. Experts advise continuing biologics and thiopurines, avoiding small-molecule IBD drugs during pregnancy and lactation, considering low-dose aspirin when preeclampsia risk is elevated, and managing all IBD pregnancies as high-risk. This could inform prescribing and payer reviews pending full data.

Next, the Preeclampsia Foundation was selected as an Action for Women’s Health awardee within Pivotal’s 250 million dollar initiative managed by Lever for Change. The grant recognizes work across hypertensive disorders of pregnancy and will support prediction, prevention, management, and postpartum follow-up.

Roche reported that oral SERD giredestrant met the primary endpoint of invasive disease-free survival in the Phase 3 lidERA adjuvant study for early ER+/HER2− breast cancer. Overall survival is immature with a positive trend, and safety was consistent. This is the first Phase 3 oral SERD to show a significant benefit versus standard endocrine monotherapy in this setting, with data heading to regulators and a future medical meeting.

From the Americas, Brazil, Chile, and El Salvador shared progress toward cervical cancer elimination. Brazil highlighted high HPV vaccination coverage, adoption of a single-dose schedule, and rollout of a national HPV DNA test, with expansion planned by the end of 2026, signaling scale-up for screening and follow-up.

WHO and IARC launched a free cervical precancer learning program on WHO Academy for officials, clinicians, and community health workers. The modules support the 90–70–90 targets for 2030 by strengthening screening, triage, and treatment capacity.

In oncology R&D, the BCL-XL degrader DT2216 began dosing in a Dana-Farber Phase 1b 2 study with weekly paclitaxel in platinum-resistant ovarian cancer, building on Phase 1a RP2D and preclinical tumor eradication signals. Early clinical readouts will clarify the translational potential.

On policy, Ovarian Cancer Research Alliance debuted its Center for Public Policy and an interactive map to track key bills and funding priorities, unifying federal and state advocacy and grassroots work. OCRA’s efforts have helped secure 3.8 billion dollars to date for research and education.

In digital health, Millie launched Maia, an AI agent for maternal care and clinic operations that integrates into the patient app and a unified data layer to personalize support and automate workflows, aiming to improve outcomes and reduce costs.

In Europe, Greece partnered with Sword Health to create a national AI front door to care, beginning with Health Information Line 1566 to enhance triage and coordination. Staff will be augmented by AI with independent monitoring planned, targeting faster responses and real-time system visibility.

FamilyWell Health raised 8 million dollars in Series A funding, led by New Markets Venture Partners, to expand integrated women’s mental health services across five states, advance its AI platform, and grow into perimenopause and menopause care.

Finally, Devex spotlighted more than 80 Action for Women’s Health awardees funded by Pivotal with Lever for Change. Themes include locally driven models, digital access, and social determinants, responding to chronic underfunding in women-specific health.

Stay ahead in Women’s Health research! Like, share, and subscribe for our updates. Visit www.lqventures.com
or email us at info@lqventures.com for expert healthcare consulting. See you next time!

Why It Matters

ER+/HER2− early breast cancer has high recurrence risk, so oral SERDs with adjuvant benefit could shift endocrine standards.
Cervical cancer elimination hinges on workforce training and program logistics as much as vaccine supply.
AI deployments in maternal care and national triage lines test whether data platforms can deliver safer, faster access.
Integrated mental health in OB/GYN settings addresses a leading driver of maternal mortality.
Policy infrastructure and advocacy tools can unlock funding and access for gynecologic cancers.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Women’s health archive on our research hub page.

FAQ

What did Roche’s lidERA trial show for giredestrant?

Roche reported a statistically significant and clinically meaningful invasive disease-free survival advantage vs standard endocrine monotherapy in early ER+/HER2− breast cancer at interim analysis. OS was immature with a positive trend, and safety was consistent with prior profiles [3].

How will OCRA’s new Center for Public Policy be used?

It consolidates federal and state advocacy, grassroots programs, and launches an interactive policy map to track bills and funding affecting ovarian and gynecologic cancers, aiming to strengthen national representation for patients [7].

What is Greece implementing with Sword Health?

A national AI-powered front door to healthcare, starting with the Health Information Line 1566 to enhance triage, coordination, and system visibility, with independent monitoring for safety and performance [9].

How is FamilyWell using its $8M raise?

To scale integrated women’s mental health services nationally, expand into perimenopause and menopause, and advance AI-enabled platforms and provider training via FamilyWell Academy [10].

What support is WHO/IARC offering for cervical precancer programs?

A free WHO Academy learning program with modules for providers and managers to build screening, diagnosis, and management capacity toward the 90–70–90 targets by 2030 [5].

What is Dialectic’s DT2216 targeting in ovarian cancer?

DT2216 is a selective BCL-XL degrader. A Phase 1b/2 with weekly paclitaxel has begun dosing in PROC, building on Phase 1a RP2D and strong preclinical activity in HGSOC models [6].

Entities / Keywords

Roche; giredestrant; lidERA; SERD; ER+/HER2− breast cancer • PAHO; HPV vaccination; HPV DNA test; cervical cancer elimination • IARC; WHO Academy; 90–70–90 • Dialectic Therapeutics; DT2216; BCL-XL; PROC • OCRA; Center for Public Policy; advocacy map • Millie; Maia AI; maternal care • Sword Health; Greece; AI triage • FamilyWell Health; women’s mental health; perimenopause; menopause • IBD pregnancy guidelines; biologics; thiopurines; low-dose aspirin.